The diagnosis of myelodysplastic syndromes (MDS) currently relies primarily on the morphological assessment of the patient's bone marrow and peripheral blood cells.
Introduction
The myelodysplastic syndromes (MDS) are clonal hematopoietic disorders which are characterized by ineffective hematopoiesis and a variable propensity to evolve to AML 1 . Standard diagnostic criteria for MDS and its various subtypes, utilizing either the older French-American-British (FAB) classification 2 or the more recent WHO classification [3] [4] [5] [6] rely heavily on the subjective morphologic evaluation of bone marrow cells.
Given the variable course of individual cases of MDS, several prognostic scoring systems have been proposed to predict survival and probability of leukemic evolution. The two most widely used systems; the International Prognostic Scoring System (IPSS) 7 and the WHO classification-based prognostic scoring system (WPSS) 8 have both been shown to have prognostic value. However, both systems include observer-dependent criteria The first report of a microarray-based GEP schema for hematological malignancies used an unsupervised, class discovery approach to uncover the molecular distinctions between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) 12 , and demonstrated that a GEP strategy could accurately subdivide
For personal use only. on January 25, 2018 . by guest www.bloodjournal.org From acute leukemias [13] [14] [15] . Subsequently, a number of microarray-based GEP studies of MDS, mostly utilizing purified CD34+ or AC133+ cell populations, have been published. Several studies compared gene signatures between MDS and the healthy individuals, between different risk groups of MDS, or between MDS-derived AML and de novo AML [16] [17] [18] [19] . While these studies have provided important molecular insights into the pathophysiology of MDS, they were not designed to test the diagnostic or prognostic capabilities of GEP in this group of diseases.
The international multi-institutional Microarray Innovations in Leukemia (MILE)
research program centered on the European LeukemiaNet (ELN, www.leukemianet.org) assessed the clinical utility of a microarray-based GEP assay in the diagnosis and sub-classification of 16 clinically recognized subtypes of acute and chronic leukemia. A Diagnostic Classification (DC) model, developed for and evaluated during the MILE study was also designed to distinguish leukemia from MDS and from non-leukemic conditions 20 .
While the DC model proved to be very accurate in the classification of leukemia, it failed to confirm the clinical diagnosis of MDS in half of the MDS specimens submitted to the study 21 . In the discordant cases, the DC model classification was either AML or a non-leukemic condition, referred to as "none-of-the-targets".
However, a blinded external pathologic review confirmed the initial clinical diagnosis of MDS in 94% of cases. We observed that cases of MDS classified as AML by the DC model had more aggressive disease and more rapid progression to AML, whereas MDS cases classified as "none-of-the-targets" had a more indolent clinical course. Based on this observation, we developed an improved Prognostic
Classification (PC) model. The essence of the PC model was to provide a score related to transformation to AML and overall survival for MDS patients, which was 
Methods

Patient Samples
The MILE study was approved by the relevant ethical committees in each country and each patient sample was taken at de novo presentation of the disease with ethical informed consent for research purposes in each center in accordance with the Declaration of Helsinki. Bone marrow mononuclear cells were separated by Ficoll-Hypaque technique at each center and total RNA was extracted according to the study protocol.
There are several patient datasets referred to in this manuscript ( Figure 1 ). The original cohort of MDS samples submitted to the Stage I of the MILE study consisted of 174 patients. Following external review, 10 samples were excluded leaving a cohort of 164 samples (dataset N164). Further sub-sets of N164 were defined as follows: (i) Dataset N139 included the validated MDS specimens, but excluded the CMML cases; (ii) Dataset N110 included patients in N139 for which data on survival and time to AML transformation was available; (iii) Dataset N74 was a subset of N110 and included patients with less than 18 months to AML or at least 18 months to AML; and (iv) Dataset N43 was a subset of N74 and included patients with less than 36 months to AML or at least 36 months to AML. Clinical characteristics of the N164, N139 or N110 MDS patient groups are shown in Table 1 
RNA extraction
The methods used for RNA isolation, cRNA preparation and labeling, microarray analysis, quality control and normalization of microarray data were as previously described 22 .
For each specimen, i.e. Ficoll-banded bone marrow mononuclear cells, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT) 24 -T7 primer (Roche Applied Science, Mannheim, Germany) and the Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cDNA was purified using the GeneChip® Sample Cleanup
Module (Affymetrix). Labeled cRNA was generated using the Microarray RNA target synthesis kit (Roche Applied Science) and in vitro transcription labeling nucleotide mix (Affymetrix). The generated cRNA was purified using the GeneChip® Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). In each preparation, an amount of 11.0 µg cRNA was fragmented with 5X Fragmentation Buffer (Affymetrix) in a final reaction volume of 25 µl. The incubation steps during cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).
Hybridization, washing, staining, and scanning protocols, respectively, were performed on Affymetrix GeneChip® instruments (Hybridization Oven 640, Fluidics Station FS450, Scanner GCS3000) as recommended by the manufacturer. This procedure was well documented and all laboratories were specifically trained in precise applications of this procedure and were required to demonstrate proficiency prior to commencement of this study 22 .
Image analysis and data processing
Microarray image files (DAT files) and cell intensity files (CEL files) were generated using default Affymetrix microarray analysis parameters (GCOS 
Risk scores based on classification of groups of time to AML
The 1-nearest neighbor classification was used to build risk scores for a prognostic model with two prognostic classifiers (PC1 and PC2). Two sub-datasets of N110 were used. The dataset N74 was used to generate the classifier for the groups with less than 18 months to AML or at least 18 months to AML. The dataset N43 was used to generate a second classifier for the groups with less than 36 months to AML or at least 36 months to AML. The top-30 probe sets were used for classification of the dataset N74, and the top-70 probe sets were used for classification of the dataset N43. Detailed information on the PC probe sets is available online (Supplementary Dataset). The accuracy of LOO cross-validation was 64/74 = 86% for classification with the 18-months cut-off, and that for classification with the 36-months cut-off was 35/43 = 81%. The process of selecting probe sets was done separately for each re-iteration of cross-validation. The re-substitution of the training data back into the risk score resulted in a highly significant p-value of the log-rank For personal use only. on January 25, 2018. by guest www.bloodjournal.org From test, but in order to avoid an over-estimate of the significance, the LOO crossvalidation was used for an estimate of accuracy for the risk score.
The risk score is defined by the classification results. For a given gene expression profile, we first applied the 1-nearest neighbor classifier of N74 in the Euclidean space of 30 probe sets to determine whether the subject will transfer to AML in less than 18 months. If yes, the risk score was 2. Otherwise, we applied the 1-nearest neighbor classifier of N43 in the Euclidean space of 70 probe sets to determine whether the subject will transform to AML in less than 36 months. If yes, the risk score was 1, otherwise the risk score was 0. For the leave-one-out approach, the sizes of the training data sets were 73 and 42, instead of 74 and 43, respectively.
The significance of differences in time of transformation to AML and overall survival was assessed by the log-rank test for the Kaplan-Meier plots. Various covariates were compared with the hazard ratios. The multi-gene classification models rely on all genes in the model, with each gene weighted for its contribution to the model's output based on training data.
Results
MDS disease classification using the Diagnostic Classification (DC) model
Within the MILE study, 174 gene expression profiles from samples obtained at diagnosis were originally included with a clinical diagnosis of MDS. These specimens were submitted and processed in Berlin, Cardiff, Munich, or Salamanca. The diagnosis of the samples was assessed by specialists at each submission site using their individual expertise and standard diagnostic procedures. The age distribution of patients was representative of a typical non-selected MDS population, as was the distribution of MDS subtypes with a majority of samples from "low-risk" patients, and cases with a normal karyotype (Supplementary Dataset available online).
Analysis of these 174 specimens using the DC model resulted in only 49% of them being correctly called as MDS 20 from their underlying gene expression profiles. The remainder of the submitted MDS specimens was evenly split between a call into "none-of-the-targets" (24%) and AML (25%) categories, with a further 2% reporting a tie between classes, i.e. being considered as samples with low signature confidence.
There was no correlation between the classification call and the site of analysis of these specimens.
Validation of MDS samples
In order to confirm the clinical diagnosis of the submitted MDS specimens, bone marrow smears were sent for blinded review to two external experts from different institutions, who confirmed the diagnosis of MDS in 164 (94%) of the specimens.
Ten discordant specimens were removed from the subsequent analysis as a result of this review process: Six cases were reclassified as AML, which interestingly was consistent with the original class call from the DC model; and four cases were excluded from this MDS study: one CML, one CLL, one myeloma, and an incomplete slide set that did not permit external review. There was 82% concordance between the submitted and the external MDS subtype assignment of the final 164 samples.
Four cases were submitted with a generic diagnosis of "MDS" and the validated diagnoses of these were that one had RA, two had RAEB1 and one was RAEB2.
84% (n=21) of submitted CMML cases were confirmed; the remaining four patients MDS/AML/"none-of-the-targets", and one had a tie between categories AML and "none-of-the-targets".
Comparison of validated MDS samples with de novo AML and "none-of-thetargets" classes.
For a comparison analysis, exemplary MILE study data from patients submitted as AML and "none-of-the-targets" by the four contributing centers were used. These were 202 AML specimens and 69 "none-of-the-targets" gene expression profiles.
These specimens were combined with the 135 validated MDS specimens, excluding those with tied calls, for a principal component analysis (PCA) using the probe sets from the DC model (Figure 2A ). In the three-dimensional plot, a partial overlap was observed for MDS and AML, as well as for MDS and "none-of-the-targets" samples (not highlighted). The hierarchical clustering analyses ( Figure 2B ) of the same data are consistent with MDS gene expression illustrating a biological continuum from
AML to a non-leukemic disease. MDS samples do not form clear and distinct clusters, but rather are interspersed among AML or "none-of-the-targets" specimens, whilst many AML specimens form clear clusters. Notably, there was no clustering associated with processing center, age or sex. Equally, no distinct separation on the basis of IPSS was seen (Figure 3 ).
Trends were seen between MDS and DC model calls: none of the 5q-MDS samples had received an AML call (63% were called MDS; 37% were called "none-of-thetargets"); 86% of RARS specimens had received an MDS call; 68% of RAEB2 specimens had received an AML call, 32% had received MDS, and none had received a "none-of-the-targets" call; whilst only 11% of RA specimens had an AML call. Also, the influence of the blast cell count at diagnosis was investigated: 66% of the samples had <5% blasts, 19% had between 5% and 10% blasts, whilst 15% had >10% blasts. Approximately 19% of those samples called AML by the DC classifier had <5% blasts, whilst 9% of samples called "none-of-the-targets" had >5% blasts (Supplementary Figure S1) . About 7% of patients with an AML or MDS call and <5% blasts transformed. However, 17% of the patients who did transform had <5% blasts.
These results would indicate that the blast cell count was not the only parameter contributing to either AML transformation or the molecular classifications based on the gene expression microarray analysis.
A similar analysis for the 25 CMML specimens showed that 12 (48%) were called by the DC model as MDS, 6 (24%) were called AML; 5 (20%) were called as "none-ofthe-targets"; with the remaining 2 (8%) having tied calls between AML, MDS and "none-of-the-targets". These proportions were similar to those seen for the MDS cohort. With respect to the blast cell count, the CMML specimens with AML calls had a median of 5% blasts, those with MDS calls had a median of 2% blasts, and those with "none-of-the-targets" calls had a median of 3% blasts.
Prognostic outcome grouped by the Diagnostic Classification (DC) model
107 of 110 validated MDS specimens with outcome data available were uniquely classified by the DC model. The median follow-up period for these patients was 27 months. A Kaplan-Meier analysis was applied to both overall survival and time to AML transformation from diagnosis. In Figure 4A , overall survival grouped by the DC model calls showed a non-significant p-value (p=0.167) of the log rank test. The 5-year survival rates of AML, MDS and "none-of-the-targets" were 15% (n=25), 24% (n=55), and 50% (n=27). The median survival times were 26, 35 and 50 months, respectively.
However, there were significant differences (p-value of log rank test of p<8x10 -5 ) in time to AML transformation among the three molecular classification groups: none (0%) out of 27 MDS patients with a "none-of-the-targets" call; 8 (14.5%) out of 55 patients with MDS call, and 11 (44%) out of 25 patients with an AML call ( Figure 4B ).
All patients with an AML call that transformed did so within 18 months; only one patient in this group had a censor date >72 months. The 18-months AML transformation rate for MDS patients with a MDS call was 8%. No patient with a "none-of-the-targets" call by the gene expression microarray algorithm transformed to AML within 5 years.
Prognostic Classifier for MDS
The DC model had been designed to function as a diagnostic classifier for leukemia and MDS, not as a prognostic classifier. However, in light of the prognostic implications of the MDS "miscalls" using the DC, the expression data was reevaluated with the aim of producing a prognostic risk score aimed at the prediction For personal use only. on January 25, 2018. by guest www.bloodjournal.org From for three groups of MDS patients with respect to time to AML transformation: (A) less than 18 months; (B) at least 18 months and less than 36 months; and (C) more than 36 months. Two datasets were used in the development of a hierarchical microarraybased risk score: dataset N74 was used to generate a classifier for the groups A (given a risk score of 2) and B; whilst the dataset N43 was used to generate the classifier for the groups B (risk score 1) and C (risk score 0). The Kaplan-Meier curves for overall survival and time to AML transformation by the risk score and the corresponding leave-one-out (LOO) risk scores for the dataset N110 are shown in Figure 5 . Two variations of risk scores were calculated: one using re-substitution ( Figure 5B, D) and a second method of using leave-one-out cross-validation ( Figure   5C , E). Both analyses showed highly significant differences between the groups for overall survival ( Figure 5B, C) and time to AML transformation ( Figure 5D, E) . A nonhierarchical method, in which the resulting score of 0 or 1 from each of the two classifiers were combined, also resulted in significant separation of the three patient groups (Supplementary Figure S2) .
Co-variate analysis
To further assess the effects of covariates of interest, we calculated the hazard ratios in Cox proportional hazards models. Table 2 lists the univariate and multivariate hazard ratios of the IPSS, diagnostic groups (5q-, RA, RARS, RAEB1, RAEB2 and RCMD), the DC and PC microarray models. For time to AML transformation, the diagnostic WHO group was not significant (p-value = 0.0986). Similarly, for overall survival, the diagnostic group and the DC model call were not significant. The multicovariate hazard ratios showed that the PC model risk scores were more significant than IPSS for both time to AML transformation (p-value = 0.0047) and overall survival (p-value = 0.0089). Similarly, both the DC model calls and PC model scores For personal use only. on January 25, 2018. by guest www.bloodjournal.org From were more significant than the individual IPSS components, i.e., blast count score, karyotype score, and cytopenia score ( Table 2 ).
Molecular pathway analysis
The genes (probe sets) used by the DC and PC microarray models were further studied with a pathway analysis application. Gene-by-gene interactions for the model classes is shown in Supplementary Figures S3 and S4 .
Discussion
The Gene Expression Profiling working group (WP13) of the European LeukemiaNet For personal use only. on January 25, 2018. by guest www.bloodjournal.org From association with time to AML transformation, but not to overall survival. However, it should be noted that the lack of correlation with IPSS 7 may have been expected as this scoring system was based on only 25% of patients, in each risk category, undergoing evolution to acute myeloid leukemia. Interestingly, those patients with an AML classification call that did transform did so within 18 months from diagnosis, whilst none of the patients with the "none-of-the-targets" call transformed. The majority of patients with a MDS classification result, who did transform to AML, did so more slowly, over a 5 year period. This discrepancy was exploited for the development of a time to AML transformation risk score by subdividing patients into early and late transformers. The Kaplan Meier analysis, univariate and multivariate hazard ratios all showed high significance using the risk score calculated with the leave-one-out approach.
Pathway analysis of the genes contributing to the discrimination between the MDS molecular subgroups identified several networks that are involved in the progression from "none-of-the-targets" through MDS to AML with several pathways indicating that these are involved in both steps of disease progression. A similar analysis of the pathways and interacting genes from the leave-one-out risk scores highlights several genes known to be actively involved in acute myeloid leukemia including HOX cluster genes, FLT3, KIT, RUNX1 and WT1. HOX genes often form the basis of gene expression profiling lists in studies on AML [29] [30] [31] [32] . The other candidate genes are also often mutated in AML and have prognostic significance particularly in AML patients a normal karyotype [33] [34] [35] [36] [37] . Furthermore, some of the genes are associated with therapy-related progression from MDS to AML 38 .
In conclusion, the DC model, evaluated as part of the MILE study program, was designed and built for improving clinical diagnosis but did not show the same high
For personal use only. on January 25, 2018. by guest www.bloodjournal.org From accuracy for MDS compared with the other 16 lymphoid or myeloid acute leukemia diagnostic subgroups. However, an expected, and significant, correlation with the time to AML transformation was observed which led to the development of a prognostic algorithm that can identify MDS patients with high, intermediate and low risk of progression to AML, based only on the respective gene expression profiles from a microarray analysis. Thus, the molecular signatures may go beyond morphology, phenotype and cytogenetics by removing any subjective assessment with an objective assessment based on a series of measurements of specific RNA levels using microarrays independent of any of these parameters. In addition, the genes involved in the predictive scores may also allow the development of targeted therapies for MDS patients with poor prognosis. 
Risk (LOO)
0 1 2 0 1 2 For personal use only. on January 25, 2018. by guest www.bloodjournal.org From
